64 related articles for article (PubMed ID: 35464460)
1. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
2. Gastrodin synergistically increases migration of interleukin-13 receptor α2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study.
Huang S; Bai Y; An Z; Xu C; Zhang C; Wang F; Zhong C; Zhong X
Phytother Res; 2023 Dec; 37(12):5947-5957. PubMed ID: 37748098
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract][Full Text] [Related]
4. Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.
Kashyap D; Salman H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612592
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
Tomishima K; Fujisawa T; Fukumura Y; Ushio M; Fukuma T; Takahashi S; Takasaki Y; Suzuki A; Ito K; Ishii S; Yao T; Nagahara A; Isayama H
Pancreas; 2022 Oct; 51(9):1133-1139. PubMed ID: 37078936
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.
Ou W; Marino MP; Suzuki A; Joshi B; Husain SR; Maisner A; Galanis E; Puri RK; Reiser J
Hum Gene Ther Methods; 2012 Apr; 23(2):137-47. PubMed ID: 22612657
[TBL] [Abstract][Full Text] [Related]
7. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.
Strober W; Kitani A; Fichtner-Feigl S; Fuss IJ
Curr Mol Med; 2009 Aug; 9(6):740-50. PubMed ID: 19689301
[TBL] [Abstract][Full Text] [Related]
8. The innate antiviral response upregulates IL-13 receptor α2 in bronchial fibroblasts.
Campbell-Harding G; Sawkins H; Bedke N; Holgate ST; Davies DE; Andrews AL
J Allergy Clin Immunol; 2013 Mar; 131(3):849-55. PubMed ID: 23069489
[TBL] [Abstract][Full Text] [Related]
9. IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses.
Lee CM; He CH; Nour AM; Zhou Y; Ma B; Park JW; Kim KH; Dela Cruz C; Sharma L; Nasr ML; Modis Y; Lee CG; Elias JA
Nat Commun; 2016 Sep; 7():12752. PubMed ID: 27629921
[TBL] [Abstract][Full Text] [Related]
10. IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma.
Rechberger JS; Porath KA; Zhang L; Nesvick CL; Schrecengost RS; Sarkaria JN; Daniels DJ
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631512
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging.
Leland P; Kumar D; Nimaggada S; Bauer SR; Puri RK; Joshi BH
Res Sq; 2023 Jan; ():. PubMed ID: 36711796
[TBL] [Abstract][Full Text] [Related]
12. Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide.
Jannoo R; Walker W; Kanamarlapudi V
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345109
[TBL] [Abstract][Full Text] [Related]
13. Screening and anti-glioma activity of Chiloscyllium plagiosum anti-human IL-13Rα2 single-domain antibody.
Qin L; Ren Q; Lu C; Zhu T; Lu Y; Chen S; Tong S; Jiang X; Lyu Z
Immunology; 2023 Sep; 170(1):105-119. PubMed ID: 37190788
[TBL] [Abstract][Full Text] [Related]
14. High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma.
Kim GB; Aragon-Sanabria V; Randolph L; Jiang H; Reynolds JA; Webb BS; Madhankumar A; Lian X; Connor JR; Yang J; Dong C
Bioact Mater; 2020 Sep; 5(3):624-635. PubMed ID: 32405577
[TBL] [Abstract][Full Text] [Related]
15. Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
J Transl Med; 2023 Sep; 21(1):636. PubMed ID: 37726828
[No Abstract] [Full Text] [Related]
16. Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE; Hibbard JC; Alizadeh D; Blanchard MS; Natri HM; Wang D; Ostberg JR; Aguilar B; Wagner JR; Paul JA; Starr R; Wong RA; Chen W; Shulkin N; Aftabizadeh M; Filippov A; Chaudhry A; Ressler JA; Kilpatrick J; Myers-McNamara P; Chen M; Wang LD; Rockne RC; Georges J; Portnow J; Barish ME; D'Apuzzo M; Banovich NE; Forman SJ; Badie B
Nat Med; 2024 Mar; ():. PubMed ID: 38514871
[No Abstract] [Full Text] [Related]
17. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer.
Jaén M; Martín-Regalado Á; Bartolomé RA; Robles J; Casal JI
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188802. PubMed ID: 36152905
[TBL] [Abstract][Full Text] [Related]
18. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
Liang R; Wu C; Liu S; Zhao W
Drug Deliv; 2022 Dec; 29(1):1620-1630. PubMed ID: 35612318
[TBL] [Abstract][Full Text] [Related]
19. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas.
Pawlowski KD; Duffy JT; Tiwari A; Zannikou M; Balyasnikova IV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443750
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
